Download PDF
Fortschr Neurol Psychiatr 2008; 76(3): 139-146
DOI: 10.1055/s-2007-996179
Originalarbeit
© Georg Thieme Verlag Stuttgart · New York

Psychopharmakologische Behandlung von und bei Persönlichkeitsstörungen

Psychopharmacologic Treatment of Personality DisordersA.  Quante1 , S.  Roepke1 , A.  Merkl1 , I.  Anghelescu1 , C.-H.  Lammers1
  • 1Charité, Campus Benjamin Franklin, Klinik und Hochschulambulanz für Psychiatrie und Psychotherapie (Direktorin: Prof. Isabella Heuser), Berlin
Further Information

Publication History

Publication Date:
01 February 2008 (online)

Also available at
   Permissions and Reprints
Preview

Zusammenfassung

Bis heute gibt es keine Zulassung eines Psychopharmakons für die Behandlung einer einzelnen Persönlichkeitsstörung. Lediglich für die Borderline-Persönlichkeitsstörung existiert eine Datenlage, auf deren Grundlage die Amerikanische Psychiatrische Gesellschaft die Pharmakotherapie als eine Option aufführt. Dies liegt zum einen am Mangel an doppelblinden randomisierten Studien, zum anderen an den Störungsbildern selbst. Die Persönlichkeitsstörungen zeigen eine hohe Komorbidität untereinander und eine hohe Prävalenzrate verschiedener Achse-I-Störungen (z. B. Abhängigkeitserkrankungen). Somit richtet sich eine psychopharmakologische Therapie häufig gegen bestimmte Symptome des Störungsbildes (z. B. Impulsivität) oder begleitende Achse-I-Störungen (z. B. Depressive Störungen). Dem weitgehenden Fehlen empirischer Befunde steht der häufige Einsatz von Psychopharmaka bei Persönlichkeitsstörungen gegenüber. Klinische Empfehlungen sind somit immer mit dieser Einschränkung zu beurteilen.

Grundsätzlich sollte bei der Therapie von Patienten mit einer Persönlichkeitsstörung die pharmakologische Behandlung immer gemeinsam mit einer psychotherapeutischen Intervention erfolgen. Besonders die schwerwiegenden Symptome wie unkontrollierbare Impulsivität, Aggressivität, depressive, dissoziative, ängstliche oder psychotische Symptome können Zielsymptomatik einer Pharmakotherapie sein. So wird derzeit empfohlen, depressive Syndrome und auch Impulsivität mit Serotoninwiederaufnahmehemmern, aggressives und impulsives Verhalten unter anderem mit Stimmungsstabilisierern und psychotische Syndrome mit atypischen Antipsychotika zu behandeln, während der Einsatz von Benzodiazepinen und die Bedarfsmedikation mit niederpotenten, sedierenden Antipsychotika vermieden werden sollte. Weiterhin kommen je nach Syndrom beispielsweise α2-Agonisten, µ-Opiat-Antagonisten und Omega-3-Fettsäuren zum Einsatz. Es ist weiterhin zu beachten, dass die aktuellen empirischen Befunde nicht für eine Polypragmasie sprechen. Sehr wichtig ist auch, dass bei der pharmakologischen Behandlung potenzielle Nebenwirkungen (z. B. sexuelle Funktionsstörungen oder Gewichtszunahme) mit den Patienten besprochen werden. Es sollte immer eine sorgfältige Nutzen/Risiko-Abwägung erfolgen.

Dieser Übersichtsartikel soll die derzeitigen pharmakologischen Interventionsmöglichkeiten in Abhängigkeit von den im Vordergrund stehenden Symptomen aufzeigen.

Abstract

There is only a paucity of studies concerning the pharmacological treatment of personality disorders per se. On the other hand the clinical use of medication in these conditions is quite high, although there is no effective psychopharmacological treatment of distinct personality disorders. The psychopharmacological treatment of patients suffering from a personality disorder focuses on distinct symptoms and its comorbidity. Some symptoms could also be associated with other disorders like depression or psychosis, which often makes an exact differentiation of these disorders and a personality disorder difficult.

Since symptoms of personality disorders are ego-syntonic, chronic and very often dependent on psychosocial factors, it is unlikely that a solely psychopharmacological treatment will be successful in most patients with a personality disorder. However, severe syndromes like depressive, impulsive, aggressive, dissociative, anxious or psychotic features may render a pharmacotherapy necessary. For the treatment of depressive syndromes or impulsivity a medical therapy with serotonin reuptake inhibitors, for the treatment of psychotic syndromes a medication with atypical antipsychotics is recommended. Impulsive or aggressive behaviour could be treated with mood stabilizers as well. Furthermore, there are indications for the use of α2-agonists, µ-opiate-antagonists and omega-3 fatty acid. The general use of benzodiazepines should be avoided as well as polypragmasy. Advantages versus potential damage of a high dose pharmacotherapy should be carefully weighed against each other.

This article gives an overview over the today’s most common psychopharmacological treatment possibilities in patients with a personality disorder.

Schlüsselwörter

Persönlichkeitsstörung - Psychopharmakotherapie - Antidepressiva - atypische Antipsychotika

Key words

personality disorder - psychopharmacotherapy - antidepressives - atypical neuroleptics

Literatur

  • 1 American Psychiatric Association (APA) .Diagnostic and statistical manual of mental disorders (3rd edition). Washington, DC: American Psychiatric Association. APA 1980
    Search in Google Scholar
  • 2 Links P S, Boggild A, Sarin N. Psychopharmacology of personality disorders: review and emerging issues.  Curr Psychiatry Rep. 2001;  3 70-76
    Search in Google Scholar
  • 3 Cloninger C R. A systematic method for clinical description and classification of personality variants. A proposal.  Arch Gen Psychiatry. 1987;  44 573-588
    Search in Google Scholar
  • 4 Soloff P H. Algorithms for pharmacological treatment of personality dimensions: symptom-specific treatments for cognitive-perceptual, affective, and impulsive-behavioral dysregulation.  Bull Menninger Clin. 1998;  62 195-214
    Search in Google Scholar
  • 5 Links P S, Steiner M. Psychopharmacologic management of patients with borderline personality disorder.  Can J Psychiatry. 1988;  33 355-359
    Search in Google Scholar
  • 6 Soloff P H. Psychopharmacology of borderline personality disorder.  Psychiatr Clin North Am. 2000;  23 169-92, ix
    Search in Google Scholar
  • 7 Paris J. Recent advances in the treatment of borderline personality disorder.  Can J Psychiatry. 2005;  50 435-441
    Search in Google Scholar
  • 8 Olivier B, Mos J, Oorschot R van, Hen R. Serotonin receptors and animal models of aggressive behavior.  Pharmacopsychiatry. 1995;  28 Suppl 2 80-90
    Search in Google Scholar
  • 9 Sass H, Jünemann K. Affective disorders, personality and personality disorders.  Acta Psychiatr Scand Suppl. 2003;  418 34-40
    Search in Google Scholar
  • 10 Saß H. Diagnostische Kriterien DSM-IV-TR. Wittchen, H.U. Zaudig M. Houben I 2000. Ref Type: Generic
    Search in Google Scholar
  • 11 Kendler K S, Masterson C C, Davis K L. Psychiatric illness in first-degree relatives of patients with paranoid psychosis, schizophrenia and medical illness.  Br J Psychiatry. 1985;  147 524-531
    Search in Google Scholar
  • 12 Moller H J. Management of the negative symptoms of schizophrenia: new treatment options.  CNS Drugs. 2003;  17 793-823
    Search in Google Scholar
  • 13 Tsuang M T, Stone W S, Faraone S V. Schizophrenia: a review of genetic studies.  Harv Rev Psychiatry. 1999;  7 185-207
    Search in Google Scholar
  • 14 Kendler K S, McGuire M, Gruenberg A M, O'Hare A, Spellman M, Walsh D. The Roscommon Family Study. III. Schizophrenia-related personality disorders in relatives.  Arch Gen Psychiatry. 1993;  50 781-788
    Search in Google Scholar
  • 15 Kety S S. Mental illness in the biological and adoptive relatives of schizophrenic adoptees: findings relevant to genetic and environmental factors in etiology.  Am J Psychiatry. 1983;  140 720-727
    Search in Google Scholar
  • 16 Siever L J, Davis K L. The pathophysiology of schizophrenia disorders: perspectives from the spectrum.  Am J Psychiatry. 2004;  161 398-413
    Search in Google Scholar
  • 17 Fenton W S, McGlashan T H. Risk of schizophrenia in character disordered patients.  Am J Psychiatry. 1989;  146 1280-1284
    Search in Google Scholar
  • 18 Hoch P H, Cattell J P, Strahl M O, Pennes H H. The course and outcome of pseudoneurotic schizophrenia.  Am J Psychiatry. 1962;  119 106-115
    Search in Google Scholar
  • 19 Coccaro E F. Clinical outcome of psychopharmacologic treatment of borderline and schizotypal personality disordered subjects.  J Clin Psychiatry. 1998;  59 Suppl 1 30-35
    Search in Google Scholar
  • 20 Jensen H V, Andersen J. An open, noncomparative study of amoxapine in borderline disorders.  Acta Psychiatr Scand. 1989;  79 89-93
    Search in Google Scholar
  • 21 Frankenburg F R, Zanarini M C. Clozapine treatment of borderline patients: a preliminary study.  Compr Psychiatry. 1993;  34 402-405
    Search in Google Scholar
  • 22 Serban G, Siegel S. Response of borderline and schizotypal patients to small doses of thiothixene and haloperidol.  Am J Psychiatry. 1984;  141 1455-1458
    Search in Google Scholar
  • 23 Hymowitz P, Frances A, Jacobsberg L B, Sickles M, Hoyt R. Neuroleptic treatment of schizotypal personality disorders.  Compr Psychiatry. 1986;  27 267-271
    Search in Google Scholar
  • 24 Hori A. Pharmacotherapy for personality disorders.  Psychiatry Clin Neurosci. 1998;  52 13-19
    Search in Google Scholar
  • 25 Koenigsberg H W, Reynolds D, Goodman M. et al . Risperidone in the treatment of schizotypal personality disorder.  J Clin Psychiatry. 2003;  64 628-634
    Search in Google Scholar
  • 26 Salzman C, Wolfson A N, Schatzberg A. et al . Effect of fluoxetine on anger in symptomatic volunteers with borderline personality disorder.  J Clin Psychopharmacol. 1995;  15 23-29
    Search in Google Scholar
  • 27 Kavoussi R J, Liu J, Coccaro E F. An open trial of sertraline in personality disordered patients with impulsive aggression.  J Clin Psychiatry. 1994;  55 137-141
    Search in Google Scholar
  • 28 Torgersen T, Gjervan B, Rasmussen K. ADHD in adults: a study of clinical characteristics, impairment and comorbidity.  Nord J Psychiatry. 2006;  60 38-43
    Search in Google Scholar
  • 29 Widiger T A, Weissman M M. Epidemiology of borderline personality disorder.  Hosp Community Psychiatry. 1991;  42 1015-1021
    Search in Google Scholar
  • 30 Schmahl C, Bohus M. [Symptom-focussed drug therapy in borderline personality disorder].  Fortschr Neurol Psychiatr. 2001;  69 310-321
    Search in Google Scholar
  • 31 Skodol A E, Oldham J M, Gallaher P E. Axis II comorbidity of substance use disorders among patients referred for treatment of personality disorders.  Am J Psychiatry. 1999;  156 733-738
    Search in Google Scholar
  • 32 Zanarini M C, Frankenburg F R, Hennen J, Reich D B, Silk K R. Axis I comorbidity in patients with borderline personality disorder: 6-year follow-up and prediction of time to remission.  Am J Psychiatry. 2004;  161 2108-2114
    Search in Google Scholar
  • 33 Markovitz P J, Calabrese J R, Schulz S C, Meltzer H Y. Fluoxetine in the treatment of borderline and schizotypal personality disorders.  Am J Psychiatry. 1991;  148 1064-1067
    Search in Google Scholar
  • 34 Reist C, Nakamura K, Sagart E, Sokolski K N, Fujimoto K A. Impulsive aggressive behavior: open-label treatment with citalopram.  J Clin Psychiatry. 2003;  64 81-85
    Search in Google Scholar
  • 35 Markovitz P J, Wagner S C. Venlafaxine in the treatment of borderline personality disorder.  Psychopharmacol Bull. 1995;  31 773-777
    Search in Google Scholar
  • 36 Anghelescu I, Janen B, Schindler F, Lammers C H. Worsening of borderline symptoms under reboxetine treatment.  J Neuropsychiatry Clin Neurosci. 2005;  17 559-560
    Search in Google Scholar
  • 37 Soloff P H, George A, Nathan R S, Schulz P M, Perel J M. Paradoxical effects of amitriptyline on borderline patients.  Am J Psychiatry. 1986;  143 1603-1605
    Search in Google Scholar
  • 38 Bellino S, Paradiso E, Bogetto F. Oxcarbazepine in the treatment of borderline personality disorder: a pilot study.  J Clin Psychiatry. 2005;  66 1111-1115
    Search in Google Scholar
  • 39 Stanford M S, Helfritz L E, Conklin S M. et al . A comparison of anticonvulsants in the treatment of impulsive aggression.  Exp Clin Psychopharmacol. 2005;  13 72-77
    Search in Google Scholar
  • 40 Nickel M K, Nickel C, Kaplan P. et al . Treatment of aggression with topiramate in male borderline patients: a double-blind, placebo-controlled study.  Biol Psychiatry. 2005;  57 495-499
    Search in Google Scholar
  • 41 Soloff P H, Cornelius J, George A, Nathan S, Perel J M, Ulrich R F. Efficacy of phenelzine and haloperidol in borderline personality disorder.  Arch Gen Psychiatry. 1993;  50 377-385
    Search in Google Scholar
  • 42 Benedetti F, Sforzini L, Colombo C, Maffei C, Smeraldi E. Low-dose clozapine in acute and continuation treatment of severe borderline personality disorder.  J Clin Psychiatry. 1998;  59 103-107
    Search in Google Scholar
  • 43 Zanarini M C, Frankenburg F R, Parachini E A. A preliminary, randomized trial of fluoxetine, olanzapine, and the olanzapine-fluoxetine combination in women with borderline personality disorder.  J Clin Psychiatry. 2004;  65 903-907
    Search in Google Scholar
  • 44 Soler J, Pascual J C, Campins J. et al . Double-blind, placebo-controlled study of dialectical behavior therapy plus olanzapine for borderline personality disorder.  Am J Psychiatry. 2005;  162 1221-1224
    Search in Google Scholar
  • 45 Rocca P, Marchiaro L, Cocuzza E, Bogetto F. Treatment of borderline personality disorder with risperidone.  J Clin Psychiatry. 2002;  63 241-244
    Search in Google Scholar
  • 46 Villeneuve E, Lemelin S. Open-label study of atypical neuroleptic quetiapine for treatment of borderline personality disorder: impulsivity as main target.  J Clin Psychiatry. 2005;  66 1298-1303
    Search in Google Scholar
  • 47 Nickel M K, Muehlbacher M, Nickel C. et al . Aripiprazole in the treatment of patients with borderline personality disorder: a double-blind, placebo-controlled study.  Am J Psychiatry. 2006;  163 833-838
    Search in Google Scholar
  • 48 Kellner M. Aripiprazole in a therapy-resistant patient with borderline personality and post-traumatic stress disorder.  Pharmacopsychiatry. 2007;  40 41
    Search in Google Scholar
  • 49 Mobascher A, Mobascher J, Schlemper V, Winterer G, Malevani J. Aripiprazole pharmacotherapy of borderline personality disorder.  Pharmacopsychiatry. 2006;  39 111-112
    Search in Google Scholar
  • 50 Swann A C, Birnbaum D, Jagar A A, Dougherty D M, Moeller F G. Acute yohimbine increases laboratory-measured impulsivity in normal subjects.  Biol Psychiatry. 2005;  57 1209-1211
    Search in Google Scholar
  • 51 Philipsen A, Richter H, Schmahl C. et al . Clonidine in acute aversive inner tension and self-injurious behavior in female patients with borderline personality disorder.  J Clin Psychiatry. 2004;  65 1414-1419
    Search in Google Scholar
  • 52 Schmahl C, Stiglmayr C, Bohme R, Bohus M. [Treatment of dissociative symptoms in borderline patients with naltrexone].  Nervenarzt. 1999;  70 262-264
    Search in Google Scholar
  • 53 Zanarini M C, Frankenburg F R. omega-3 Fatty acid treatment of women with borderline personality disorder: a double-blind, placebo-controlled pilot study.  Am J Psychiatry. 2003;  160 167-169
    Search in Google Scholar
  • 54 Faravelli C, Zucchi T, Viviani B. et al . Epidemiology of social phobia: a clinical approach.  Eur Psychiatry. 2000;  15 17-24
    Search in Google Scholar
  • 55 Davidson J R. Pharmacotherapy of social phobia.  Acta Psychiatr Scand Suppl. 2003;  417 65-71
    Search in Google Scholar
  • 56 Liebowitz M R, Gelenberg A J, Munjack D. Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder.  Arch Gen Psychiatry. 2005;  62 190-198
    Search in Google Scholar
  • 57 Reich J, Noyes Jr R, Troughton E. Dependent personality disorder associated with phobic avoidance in patients with panic disorder.  Am J Psychiatry. 1987;  144 323-326
    Search in Google Scholar
  • 58 Baer L, Jenike M A, Ricciardi J N. et al . Standardized assessment of personality disorders in obsessive-compulsive disorder.  Arch Gen Psychiatry. 1990;  47 826-830
    Search in Google Scholar
  • 59 Zohar J, Insel T R. Obsessive-compulsive disorder: psychobiological approaches to diagnosis, treatment, and pathophysiology.  Biol Psychiatry. 1987;  22 667-687
    Search in Google Scholar
  • 60 Ansseau M, Troisfontaines B, Papart P, Frenckell R von. Compulsive personality as predictor of response to serotoninergic antidepressants.  BMJ. 1991;  303 760-761
    Search in Google Scholar
  • 61 Cornelius J R, Soloff P H, Perel J M, Ulrich R F. Fluoxetine trial in borderline personality disorder.  Psychopharmacol Bull. 1990;  26 151-154
    Search in Google Scholar
  • 62 Silva H, Jerez S, Paredes A. et al . [Fluoxetine in the treatment of borderline personality disorder].  Actas Luso Esp Neurol Psiquiatr Cienc Afines. 1997;  25 391-395
    Search in Google Scholar
  • 63 Simpson E B, Yen S, Costello E. et al . Combined dialectical behavior therapy and fluoxetine in the treatment of borderline personality disorder.  J Clin Psychiatry. 2004;  65 379-385
    Search in Google Scholar
  • 64 Ekselius L, Knorring L von. Personality disorder comorbidity with major depression and response to treatment with sertraline or citalopram.  Int Clin Psychopharmacol. 1998;  13 205-211
    Search in Google Scholar
  • 65 Bogenschutz M P, George N H. Olanzapine versus placebo in the treatment of borderline personality disorder.  J Clin Psychiatry. 2004;  65 104-109
    Search in Google Scholar
  • 66 Schulz S C, Camlin K L, Berry S A, Jesberger J A. Olanzapine safety and efficacy in patients with borderline personality disorder and comorbid dysthymia.  Biol Psychiatry. 1999;  46 1429-1435
    Search in Google Scholar
  • 67 Szigethy E M, Schulz S C. Risperidone in comorbid borderline personality disorder and dysthymia.  J Clin Psychopharmacol. 1997;  17 326-327
    Search in Google Scholar
  • 68 Pinto O C, Akiskal H S. Lamotrigine as a promising approach to borderline personality: an open case series without concurrent DSM-IV major mood disorder.  J Affect Disord. 1998;  51 333-343
    Search in Google Scholar
  • 69 Tritt K, Nickel C, Lahmann C. et al . Lamotrigine treatment of aggression in female borderline-patients: a randomized, double-blind, placebo-controlled study.  J Psychopharmacol. 2005;  19 287-291
    Search in Google Scholar
  • 70 Kavoussi R J, Coccaro E F. Divalproex sodium for impulsive aggressive behavior in patients with personality disorder.  J Clin Psychiatry. 1998;  59 676-680
    Search in Google Scholar
  • 71 Hollander E, Swann A C, Coccaro E F, Jiang P, Smith T B. Impact of trait impulsivity and state aggression on divalproex versus placebo response in borderline personality disorder.  Am J Psychiatry. 2005;  162 621-624
    Search in Google Scholar
  • 72 Roth A S, Ostroff R B, Hoffman R E. Naltrexone as a treatment for repetitive self-injurious behaviour: an open-label trial.  J Clin Psychiatry. 1996;  57 233-237
    Search in Google Scholar

Dr. med. Arnim Quante

Charité - Universitätsmedizin Berlin, Campus Benjamin Franklin, Klinik und Hochschulambulanz für Psychiatrie und Psychotherapie

Eschenallee 3

14050 Berlin

Email: arnim.quante@charite.de